Active programs across discovery, immunotherapy, metabolism, and translation.

This research arm investigates how genetic, epigenetic, and signaling programs regulate hematopoietic stem cell self-renewal and differentiation in normal and diseased states.

The lab has highlighted how mitochondrial metabolism, including components of the succinate dehydrogenase complex, contributes to disease pathology and therapeutic opportunity.

Projects in this area include genetically engineered mouse models, metabolism-focused mechanism studies, and translational programs aimed at new therapies for MDS and related diseases.

Solid tumors such as hepatocellular carcinoma create hostile immune microenvironments and physical barriers that reduce the effectiveness of conventional therapies.

The lab is developing CAR T-cell-based approaches that not only recognize tumor cells but also reshape the tumor microenvironment and deliver therapeutic payloads directly into the tumor site.

This work underpins translational programs such as PH102 and related spin-out activity focused on moving promising assets toward clinical development.

Cancer-associated cachexia causes severe weight and muscle loss and undermines treatment tolerance, quality of life, and survival.

The Huang Lab studies how tumors communicate with distant tissues to drive systemic metabolic disruption, muscle wasting, and adipose depletion.

This interdisciplinary program connects cancer biology, metabolism, immunology, and clinical translation with the goal of developing new diagnostics and therapies.

Commercial translation is built into the lab’s research model, connecting discovery science with diagnostics, therapeutic product development, manufacturing readiness, and venture formation.

Current examples include spin-out companies and preclinical assets that move programs from academic proof-of-concept toward broader patient impact.